Promethera Biosciences

What Promethera Biosciences does

Promethera Biosciences is a Belgium-based, privately held biopharmaceutical company founded in 2009 and headquartered in Mont-Saint-Guibert that develops cell therapy products for the treatment of liver diseases. The company operates in the advanced therapy medicinal product (ATMP) domain, building biological assets aimed at patients with liver disorders, and has expanded its capabilities through inorganic moves, including the April 2018 acquisition of Baliopharm.

The company has funded its development through a sustained series of equity rounds totaling approximately $149 million between 2010 and 2019, drawing a mix of specialized life-sciences investors (EQT Life Sciences, Vesalius Biocapital Partners, Fund+, S.R.I.W.), Belgian public investors (SFPI-FPIM, Limburgse Reconversie Maatschappij), strategic corporate investors (Boehringer Ingelheim and its Venture Fund, Shire), and Asian institutional and corporate backers (Mitsui Global Investment, Mitsubishi UFJ Capital, Shibuya Kogyo, Shinsei Corporate Investment, Sansei Capital Investment, Sony Innovation Fund, Pegasus Tech Ventures). The leadership team is led by CEO and President John Tchelingerian, with Claude Dedry as Chief Operating Officer, William Macias as Chief Medical Officer ad interim, and Bertrand Lellouche as Group CFO, and the organization employs between 101 and 250 people.

No commercial product, pricing structure, revenue model, partnership economics, customer base, or product pipeline detail is disclosed in the available input data. The company remains private and pre-commercial in the observable record, with strategic activity concentrated in capital raising and selective M&A. The website scrape associated with the firmographic record contained unrelated Vietnamese-language sports news content rather than biotech-specific company information, limiting the granularity of first-party operational data.

Name

Promethera Biosciences

Website

https://promethera.com

Company type

Private

Founded year

2009

Headcount range

101–250 employees

Short description

Promethera Biosciences is a privately held Belgium-based biopharmaceutical company founded in 2009 that develops cell therapy products to treat liver diseases, having raised approximately $149 million across multiple funding rounds through 2019.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Hepatology & Liver Disease (HLAKAEAB), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Cell therapy products
• Liver disease treatments
• Biopharmaceutical development
• Regenerative medicine
• Hepatology therapeutics

Headquarters

HQ city

Mont-saint-guibert

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Core offering

Promethera Biosciences develops and manufactures cell therapy products aimed at treating liver diseases. The company operates as a biopharmaceutical firm focused on biological therapeutics for hepatic conditions, including advanced therapies derived from cell-based platforms. Its work centers on translating cell therapy science into treatments for patients with serious liver disorders.

Product overview

Promethera.com is a unified sports news portal that aggregates and publishes Vietnamese-language content across three sports verticals: football (bóng đá), baseball (bóng chày), and table tennis (bóng bàn). The platform publishes educational articles about sports rules, techniques, equipment, player profiles, stadium histories, and transfer news.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell therapy products for liver diseases

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights4 records

Direct peers

• Promethera Biosciences (HepaStem asset): Note: Promethera Biosciences is the subject company; this row is intentionally not used as a peer.
• Lygenesis: Clinical-stage cell therapy company developing allogeneic liver cell therapies delivered via lymph node injection to regenerate liver function. Directly comparable to Promethera's HepaStem approach in liver disease indications.
• Allogene Therapeutics: Clinical-stage allogeneic CAR T cell therapy developer. Comparable as an allogeneic cell therapy platform company with similar manufacturing, regulatory, and development challenges, though focused on oncology rather than liver disease.
• Atara Biotherapeutics: Allogeneic T-cell therapy developer with off-the-shelf platform. Comparable business model as an allogeneic cell therapy company with similar manufacturing approach and clinical development timelines.

Emerging players

• MiNA Therapeutics: UK-based clinical-stage biotech developing RNA-based therapeutics for liver disease and cancer. Comparable as a liver-focused biotech with platform technology targeting similar indications, though using RNA activation rather than cell therapy.
• Humacyl Pharma: Earlier-stage cell therapy company developing regenerative therapies. Comparable as a smaller cell therapy peer in the regenerative medicine space.

Broad incumbents

• Terumo BCT: Established cell and blood processing technology provider. Comparable as an infrastructure player in the cell therapy ecosystem, though serving the broader cell therapy industry rather than competing in liver disease specifically.
• Vertex Pharmaceuticals: Major biopharmaceutical company with significant cell therapy programs (via ViaCyte acquisition for diabetes) and broader hepatology franchise through CF treatments. Comparable as a well-capitalized player moving into cell therapy.
• Takeda Pharmaceutical (Shire): Global pharmaceutical company and Promethera investor (via Shire acquisition). Has significant hepatology and rare disease franchises and could serve as an exit/partner for Promethera's liver programs.
• Roche: Major pharmaceutical company with significant hepatology franchise (e.g., Pegasys, hepatitis treatments). Relevant as a potential commercial partner or acquirer for liver disease therapies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/promethera
• LinkedInlinkedin.com/company/promethera-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promethera Biosciences